Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings

U.S. equities mostly advanced Thursday, with the Dow Jones gaining 0.52% and the S&P 500 up 0.23%, while the NASDAQ remained flat. Market sentiment was buoyed by Delta Air Lines' stronger-than-expected second-quarter results, including operating revenue of $16.65 billion and adjusted EPS of $2.10, both exceeding consensus, leading the airline to reinstate its full-year 2025 guidance. This positive corporate performance was complemented by favorable economic data, as U.S. initial jobless claims declined more than anticipated to 227,000, signaling continued labor market resilience.

Analysis

The U.S. market exhibited divergent performance, with the Dow Jones gaining 0.52% and the S&P 500 rising 0.23%, while the tech-heavy NASDAQ closed nearly flat, declining 0.03%. This performance was underpinned by positive economic data, as U.S. initial jobless claims fell to 227,000, beating estimates and signaling continued labor market resilience. A key corporate catalyst was Delta Air Lines (DAL), which posted stronger-than-expected Q2 results with operating revenue of $16.65 billion and adjusted EPS of $2.10, both surpassing consensus estimates. The airline's ability to beat expectations despite an 11% YoY decline in adjusted EPS, coupled with the reinstatement of its full-year 2025 guidance and lower fuel costs, provided a significant boost to market sentiment. At a micro-level, there was extreme volatility driven by specific corporate actions. M&A activity was a major driver, with DallasNews Corporation (DALN) surging 217% on an acquisition announcement and Above Food Ingredients (ABVE) gaining 425% on a merger agreement. Conversely, developments in the biopharma sector triggered sharp sell-offs, as Mereo BioPharma (MREO) and Ultragenyx (RARE) dropped 33% and 27% respectively, after an update on their Phase 3 trial was seemingly perceived as a disappointment by investors hoping for accelerated results. Additionally, CURRENC Group (CURR) fell 30% after announcing a highly dilutive public offering.

Key Decisions for Investors

• Given the divergence between the Dow and NASDAQ, investors should evaluate their sector exposures, as strength in established industrials like Delta contrasts with flatness in technology.
• Delta's strong earnings beat and reinstated guidance, supported by lower fuel costs, present a bullish case for the airline and potentially for the broader travel sector's recovery.
• The extreme price movements in DALN, MREO, and CURR highlight the significant alpha, and risk, in event-driven situations, necessitating rigorous due diligence on M&A, clinical trials, and corporate financing activities.
• The severe negative reaction to the Mereo and Ultragenyx trial update, despite its seemingly neutral content, serves as a crucial reminder of the inherent volatility and binary risk within the biotech sector, warranting a cautious and diversified approach.
• The decline in initial jobless claims below expectations reinforces the narrative of a robust labor market, which could support consumer-facing sectors but also keep the Federal Reserve's policy options open.